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Abstract: The aim of the work reported herein was to investigate the effect of various low 
molecular weight chitosans (LMWCs) on the stability of insulin using USP HPLC methods. 
Insulin was found to be stable in a polyelectrolyte complex (PEC) consisting of insulin and 
LMWC in the presence of a Tris-buffer at pH 6.5. In the presence of LMWC, the stability of 
insulin increased with decreasing molecular weight of LMWC; 13 kDa LMWC was the most 
efficient molecular weight for enhancing the physical and chemical stability of insulin. 
Solubilization of insulin-LMWC polyelectrolyte complex (I-LMWC PEC) in a reverse 
micelle (RM) system, administered to diabetic rats, results in an oral delivery system for 
insulin with acceptable bioactivity. 
Keywords: insulin; oligochitosan; low molecular weight chitosan; polyelectrolyte  
complex; stability 
 
  
OPEN ACCESS 
Mar. Drugs 2015, 13 1766 
 
 
1. Introduction 
One of the most challenging problems in the development of liquid peptide/protein pharmaceuticals 
is their physical and chemical instability. Most peptides and proteins are formulated so that they can be 
administered clinically by parenteral injections, as this is the fastest route towards commercialization. 
However, stabilization of peptides and proteins in a designated delivery system against degradation, 
particularly in the gastrointestinal tract (GIT), is a prerequisite for oral delivery. This can be carried out 
by using several excipients such as salts, amino acids, surfactants, polyhydric alcohols, and 
carbohydrates [1]. The latter include chitosans, which are composed of ȕ-(1-4)-linked D-glucosamine 
and N-acetyl-D-glucosamine units [2]. Chitosans are non-toxic, degradable, and biocompatible polymers 
that exhibit different characteristics. This allows them to be used as excipients for protein formulations 
intended for in vivo delivery of biopharmaceuticals [3]. 
The presence of free NH2 groups allows chitosan to form polyelectrolyte complexes (PECs) with 
negatively charged moieties. For example, PECs containing chitosan, alkyl-chitosan, and PEG-grafted 
alkyl-chitosan have been shown to improve insulin delivery [4,5]. Such PEC nanoparticles showed a 
pH-dependent stabilization of insulin [6]. 
Schatz et al. synthesized a partially N-sulfated chitosan. Upon acidification, nanoparticles were 
formed by electrostatic interactions between the non-sulfated protonated amine groups of chitosan and 
the negatively charged N-sulfated chitosan amines. These PECs can be used for encapsulation of 
macromolecules [7]. 
However, the main function of such PECs is to increase protein stability towards harsh conditions in 
the GIT or unfavorable storage conditions and to protect them against physical and chemical instabilities. 
PEC nanoparticles prepared by Mao et al. using chitosan, trimethyl-chitosan, PEGylated-trimethyl-chitosan, 
and insulin were unaffected by lyophilization and PECs were shown to protect insulin from degradation 
even at temperatures as high as 50 °C for 6 h [8]. LMWCs have been used to prepare the PECs employing 
poly-Ȗ-glutamic acid, which was used as a carrier for insulin, followed by enteric coating or layering 
with calcium alginate in order to allow oral administration [9]. Jintapattanakit et al. found that PECs 
prepared using trimethyl-chitosan (100 kDa) and PEG-graft-trimethyl-chitosan copolymer improve the 
stability of oral insulin [10]. Also, Song et al. reported an oral insulin delivery system based upon 
ultrathin nanofilm encapsulation technology. The proposed system can be used to load a high amount of 
insulin (90%) using chitosan (l50–190 kDa, 75% deacetylation) [11]. Additionally, it has also been 
reported that the inclusion of chitosan in lipid nanoparticles enhances the physical stability of insulin by 
protecting against proteolysis [12]. 
A novel system based on solubilization of the insulin–chitosan PEC in RM system made from  
PEG-8 caprylic/capric glycerides and glycerol-6-dioleate as emulsifying agents and dispersed in oleic 
acid, has been patented by Badwan et al. [13,14]. The function of this solubilized PEC is to reduce the 
size of particles intended for oral delivery of insulin [15]. 
Generally, studies have been undertaken by using high molecular weight chitosans, and in the vast 
majority of cases the chemical stability of insulin was not evaluated in term of insulin degradation and 
formation of its degradation products. The objective of the work reported herein was to investigate the 
influence of complexing LMWCs of different molecular weights (1.3–30 kDa) with insulin on its 
physicochemical and biological stabilities. Insulin content was monitored and examined as well as the 
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formation of high molecular weight proteins (HMWPs) of insulin. Furthermore, the system was 
evaluated for bioactivity. 
2. Results and Discussion 
2.1. HPLC Methods Verification 
Insulin (I), A-21 desamido insulin, and HMWPs were determined by using the assay and limit of 
HMWP tests as stated in the human insulin USP monograph [16]. The insulin assay method was adopted 
for evaluating insulin stability in bulk insulin powder and in injectables [17]. Additionally, the method 
was found to be convenient for evaluating the stability of insulin in other delivery systems [18]. 
In the present work, the suitability of USP HPLC methods for the determination of insulin and HMWP 
in I-LMWC PEC systems was examined. Practically, insulin may be recovered either by an  
extraction-based method with organic solvents or by hydrolysis of the carriers (PEC or RM) with an 
alkaline reagent [19]. In the current work, different extraction solvents and procedures to extract insulin 
were evaluated. Aqueous solutions (0.01 or 0.1 N HCl) and methanol at different ratios (1/1, 2/1, 1/2, 
2/3, and 3/2 v/v) were used to obtain the optimal ratio of the extraction solvent mixtures. Extraction of 
insulin from I-LMWC PEC preparations with a mixture of 0.01 M HCl and methanol at a ratio of 2/3 
(v/v) gave acceptable recoveries for insulin (>98%); moreover, the stability of insulin in such a mixture 
was retained for 24 h. 
Furthermore, the USP HPLC method parameters used for the assessment of the stability of bulk 
insulin, such as the ratio of mobile phase components and temperature [16], were evaluated for the PEC 
and RM systems. The ratio of mobile phase components (aqueous to acetonitrile) was found to be critical 
as a high acetonitrile content and a decrease in column temperature (e.g., to 35 °C) led to the precipitation 
of sulfate salt and subsequently affected the HPLC system parameters (e.g., retention time of insulin  
and resolution). 
Verification of the USP HPLC method for insulin showed a linear response for signal output versus 
insulin concentration over the concentration range of 0.9–10 mg insulin/mL with an R2 value >0.995; 
such results are in line with the acceptable verification limits [20]. The intra- and inter-day relative 
standard deviation (RSD) values were less than 2%, indicating good precision. No interfering peaks from 
the components of the delivery systems were detected. The resolution factor between insulin and A-21 
desamido insulin was >2.0, indicating that the method is specific. The method sensitivity was proved by 
low detection limit (DL) (0.02 mg/mL) and quantitation limit (QL) (0.08 mg/mL) values. Thus, the 
isocratic HPLC method developed herein is, analytically, advantageous in comparison with the 
published gradient methods [21,22]. The results of verification of the HPLC method confirmed the 
applicability of the USP HPLC method for the analysis of preparations other than injectables, such as 
polyelectrolyte systems. Consequently, the USP method can be considered as stability indicating method 
for the analysis of PEC and RM delivery systems. 
The data in Figure 1 shows representative HPLC outputs for both assay and limit of HMWP tests, 
where the peaks corresponding to insulin, A-21 desamido insulin (Figure 1A), and HMWPs (Figure 1B) 
are well resolved. The results of HPLC method verification are summarized in Table 1; all the 
verification parameters are within acceptable limits [20]. 
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(B) 
Figure 1. Representative HPLC chromatograms for (A) insulin assay (1.5 mg/mL) and (B) 
high molecular weight proteins (HMWPs) limit test (4.0 mg/mL). 
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Table 1. HPLC method verification results for insulin assay. 
Analytical Parameter Result 
Linearity Range 
- 0.9–10.0 mg/mL R2 = 0.9998 
Specificity 
- Interference 
No interference from formulation components and 
related compounds 
Precision (%) 
- Inter-day RSD (n = 3 × 3) 0.8–1.1 
- Intra-day RSD (n = 5) 0.7–0.9 
Recovery (%) 98.3 ± 0.9 
DL (mg/mL) 0.02 
QL (mg/mL) 0.08 
Stability of Solution 
- Decrease in assay at ambient condition 2.5% decrease in assay after 24 h 
System Suitability 
- Resolution between insulin and A-21 
desamido insulin 
3.7 
- Tailing factor for insulin peak <1.8 
- RSD of replicate injections <1.6% 
DL and QL: detection and quantitation limits, RSD: relative standard deviation. 
2.2. Effect of the Molecular Weight and Concentration of LMWC on Insulin Stability 
Prior to studying the effect of the molecular weight of LMWC on the stability of insulin, different 
parameters including insulin concentration (0.9–10.0 mg/mL) and solvent (water, phosphate buffer  
pH 6.5, and Tris-buffer of pH 6.5), were investigated at 50 °C for 72 h. It was found that the stability of 
insulin increases when the concentration of insulin is increased; these results agree well with reported 
data [23–26]. However, it appears from the results of the present study that a concentration of 7 mg/mL 
is sufficient for maintaining insulin stability at pH ≈ 6.0. Furthermore, Tris-buffer (an organic buffer) 
improved the stability of insulin even at low concentrations of insulin (0.9 and 1.75 mg/mL) by inhibiting 
the re-aggregation and precipitation of insulin. Also, at neutral pH, the conversion of monomeric insulin 
to form dimeric, tetrameric, and eventually hexameric insulin seems to stabilize insulin [27]. At insulin 
concentrations of 0.9–10 mg/mL, the fractional content of the degradation products A-21 desamido 
insulin and dimer did not exceed 0.4% after incubation at 50 °C for 72 h. On the other hand, other 
HMWPs were not detected over the investigated range of insulin concentration. In neutral solutions, the 
insulin molecules are associated mainly into non-covalent, Zn2+-containing hexamers [28]. The 
observation that dimer formation is independent of insulin concentration indicates that the intermolecular 
chemical reaction occurs mainly within the hexameric units and not between the hexamers in  
solution [29]. This might be due to the fact that hexamers are less susceptible to degradation [23]. 
The stability of I-LMWC PECs prepared by using LMWCs of different molecular weights  
(1.3–30 kDa) at 50 °C is shown in Figure 2A. The kinetic parameters for insulin degradation, as shown 
in Table 2, indicate a noticeable effect of molecular weight of LMWC on the extent of insulin 
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degradation in the I-LMWC PEC preparations (i.e., stability decreases with increasing molecular weight 
of LMWC). 
 
Figure 2. Stability of insulin in the presence of (A) different LMWCs (1.5 mg/mL) and (B) 
different concentrations of 13 kDa LMWC at 50 °C. Co is the initial insulin concentration 
and Ct is the insulin concentration at different periods of incubation time. The values of Ln 
(Ct/Co) are the mean of 3 replicates for each experiment (RSDs < 5%). 
  
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0 10 20 30 40 50 60 70
L
n
 (
C
t/
C
o
)
Time (hr)
No LMWC 1.3 kDa 6 kDa 13 kDa 18 kDa 30 kDa
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0 10 20 30 40 50 60 70
L
n
 (
C
t/
C
o
)
Time (h)
No LMWC 0.15 mg/mL 0.25 mg/mL
0.35 mg/mL 1.5mg/mL 3.5 mg/mL
(A)
(B)
Mar. Drugs 2015, 13 1771 
 
 
Table 2. First-order kinetic parameters for insulin–LMWC polyelectrolyte complex  
(I-LMWC PEC) degradation in the presence of different LMWCs and different 
concentrations of 13 kDa LMWC at 50 °C. 
LMWC Molecular 
Weight (kDa) *,+ 
Insulin/LMWC 
Molar Ratio 
k (h−1) × 103 t90 (h) t50 (h) R2 
0.0 - 1.2 88 587 0.2065 
1.3 1/4.5 2.2 48 315 0.8780 
6 1/1 1.6 64 423 0.4835 
13 1/0.45 2.0 52 344 0.8428 
18 1/0.3 2.5 42 274 0.8831 
30 1/0.2 2.6 41 272 0.9388 
[13 kDa LMWC] 
(mg/mL) + 
     
0.0 - 1.2 88 587 0.2065 
0.15 1/0.02 1.3 81 533 0.9200 
0.25 1/0.03 1.0 102 675 0.5871 
0.35 1/0.045 2.4 43 283 0.8388 
1.5 1/0.2 3.6 29 191 0.7704 
3.5 1/0.45 2.0 52 344 0.8428 
k: 1st order rate constant, t90 and t50: shelf-life for 90% and 50% intact potencies. + [Insulin] is 3.5 mg/mL,  
* [LMWC] is 3.5 mg/mL. 
The effect of 13 kDa LMWC concentration on the stability of I-LMWC PECs at 50 °C is shown in 
the data in Figure 2B. The results revealed a noticeable effect of increasing LMWC concentration on the 
degradation of insulin (Table 2). 
In addition, monitoring the physical stability of I-LMWC PEC indicated that the formation of a 
physically stable system depends upon the molecular weight of LMWC. For example, LMWCs of 
shorter chains formed soluble complexes, while turbidity and precipitation were observed with higher 
molecular weight LMWCs (e.g., 30 kDa). This can be explained by the fact that complex formation 
between insulin and LMWC is mainly governed by kinetic factors which leads to preferential binding 
with the shorter chains due to their flexibility [8]. On the other hand, the chemical stability of insulin 
was affected to the same extent in the presence of different molecular weight LMWCs (Figure 2A). This 
may be attributed to the ratio of ionized groups of insulin (7.0 × 1020) to chitosan (5.3 × 1021), which 
was fixed at about 1/8 in the preparation of different I-LMWC PECs by changing the molar ratio of 
insulin: LMWC 1/0.2–1/4.5 (Table 2). The number of ionizable groups was calculated on the basis of 
previously published work [15]. 
Furthermore, changing the concentration of 13 kDa LMWC showed a significant effect on insulin 
stability (Figure 2B). Insulin instability was observed mainly at high concentrations (3.5 mg/mL), while 
at lower concentrations the effect is less. This may be explained by the changes in LMWC structure and 
particle size with concentration. With increasing concentration of LMWC, the structure becomes more 
helical, leading to the formation of aggregates and a concomitant increase in particle size (see Section 2.4). 
At high concentration, such aggregates may prevent LMWC from protecting insulin (Figure 2B). 
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By monitoring the degradation of insulin as a function of molecular weight of LMWC, the fraction 
of A-21 desamido insulin (0.2% initial) increases when the molecular weight of LMWC is increased 
after 72 h incubation at 50°C (0.9, 1.1, 1.2, 1.4, and 1.6% for 1.3, 6, 13, 18, and 30 kDa LMWC, 
respectively). While the results showed an increase in the content of insulin dimer (from 0.1% to  
0.6%–0.7%) regardless of the molecular weight of LMWC. This may be attributed to the fixed ratio of 
ionized groups of insulin to LMWC. The amino groups of LMWC have the capacity to react with insulin 
by intermolecular aminolysis, resulting in transamidation between the molecules. Such a reaction can 
result in dimer formation [29]. 
However, the formation of other HMWPs increases as the molecular weight of the LMWCs increases 
(1% for 1.3 kDa and 3%–4% for 6–30 kDa LMWCs). The formation of dimers and polymers can be 
explained by the ability of free NH2 groups to react with the carbonyl groups of insulin (available in Asn 
at A-21 and B-2, and Gln available at A-5, A-15, and B-4) by intermolecular aminolysis, resulting in 
transamidation or Schiff base-mediated reactions between molecules forming HMWPs and, in parallel, 
dimer formation, probably as a result of disulfide interchange [29]. It is worth mentioning that the impact 
of HMWP formation on the quality and therapeutic usefulness of the pharmaceutical preparation is 
attributed to safety rather than efficacy. Preparation efficacy will not be affected by a decrease in the 
content of insulin. However, some of the immunological side effects associated with insulin therapy may 
be due to the presence of covalent aggregates of insulin in the therapeutic preparations, and specific 
antibodies against dimers have been identified in 30% of insulin-treated diabetic patients [30]. Dimer 
levels of 2% generated a highly hypersensitive response [31]. Accordingly, the content of HMWPs 
should be kept as low as possible. The acceptable USP limit does not allow more than 3.0% HMWPs in 
insulin pharmaceutical preparations. This indicates that during the development of insulin delivery 
systems, optimization of the system is essential to prevent the formation of HMWPs. 
2.3. Effect of the Molecular Weight of LMWC on Immunological Bioactivity of Insulin 
The ELISA method used for insulin determination was found to be linear in the range of  
0–100 µIU/mL with an R2 value of 0.868 and DL of 0.26 µIU/mL. Method recovery at the recommended 
concentration (by the kit supplier), 50 µIU/mL, was carried out; the fraction recovered was 92.7%, with 
an RSD of 6.1% (average of 3 samples). Monitoring of insulin solutions incubated at 50 °C indicated a 
loss in bioactivity of 40% after an 8 h incubation, which indicates that the method is specific and loss in 
bioactivity of insulin can be detected using ELISA. The ELISA results indicated that insulin in the 
different I-LMWC-PECs prepared with LMWC of different molecular weights (1.3–30 kDa) retained 
its bioactivity (assay > 85%) (Table 3). The ELISA method has very high sensitivity and specificity as 
it depends on the reaction of the predominant protein with a specific antibody to form a complex [32]. 
Therefore, ELISA antigenicity is considered to be an appropriate means for detection of changes of 
insulin antigenic activity [33]. The surface structure of insulin was assessed by antibodies that bind to 
the epitopes on the insulin. The ELISA results indicated that insulin in the PEC had retained its 
bioactivity. ELISA results were comparable with HPLC results, which were used to assess the integrity 
of insulin and confirmed that the receptor-binding epitopes on insulin were maintained after 
complexation with LMWC [34]. 
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Table 3. The immunological bioactivity of insulin-LMWC polyelectrolyte (I-LMWC PEC) 
of different molecular weight after incubation at 50 °C for 72 h. 
LMWC Molecular Weight (kDa) Bioactivity (%) RSD 
No LMWC 58.9 * 10.3 
1.3 91.1 3.1 
6 92.3 4.7 
13 102.9 6.7 
18 94.6 6.1 
30 97.1 5.7 
* After 8 h of incubation, RSD: relative standard deviation. 
The aforementioned stability results show a profound impact of molecular weight (i.e., chain length), 
concentration (i.e., charge ratio), pH, and buffer type of the LMWC on the development of a stable oral 
delivery systems for insulin. In the present work, the 13 kDa LMWC can be considered a suitable 
candidate to prepare the PEC and the RM systems. It showed an optimal formulation with respect to 
chemical and physical stability. Furthermore, it produced a suitable vehicle with optimal interfacial 
surface tension and nano-size particles [15], in addition to the absence of precipitation [8]. Subsequently, 
characterization and further in vitro and in vivo investigation of the bioactivity study were undertaken 
for the delivery systems prepared using the 13 kDa LMWC. 
2.4. Characterization of I-LMWC PEC and I-LMWC RM Systems 
The particle size results for I-LMWC PECs prepared using the same insulin concentration  
(3.5 mg/mL) and different concentrations of 13 kDa LMWC (1–5 mg/mL) were compared with the 
particle size results for insulin and LMWC alone. The particle size of insulin in solution was found to 
be around 5.0 nm, which indicates that it is present in its hexameric form [35]. However, the particle 
size of LMWC is concentration dependent. When the LMWC concentration is low, LMWC particles are 
present in a more extended form; however, above a certain concentration aggregates start to form and 
the particle size starts to increase; similar results have been previously reported [36]. 
At low concentration of LMWC (1 mg/mL) the size distribution intensity of I-LMWC PECs  
was 6.38 ± 0.26 nm (higher than the size of insulin), and only one peak was present when measuring 
particle size. This means that all the LMWC molecules interact with insulin molecules to form a particle 
larger than insulin. Increasing the LMWC concentration to 3.5 and 5 mg/mL resulted in a particle size  
of 6.9 ± 0.17 nm; however, another peak started to appear in the region of around 100 ± 20 nm, which 
represents the size of the free LMWC and aggregated LMWC in the sample (i.e., LMWC un-reacted 
with insulin). The results of mean particle size are shown in Figure 3A. Since LMWC will react with 
insulin at one site only, an excess amount of LMWC will be free in the sample that may also aggregate 
and give a particle size of around 100 nm. The mean particle size of the RMs was 300 ± 19 nm. 
The effect of LMWC concentration on the zeta potential of I-LMWC PEC (3.5 mg insulin/mL) was 
investigated. LMWC (1–5 mg/mL) without associated insulin shows a positive zeta-potential of  
+15–+25 mV (Figure 3A). On the other hand, the presence of insulin (with a zeta-potential of −27 mV) 
decreases the zeta-potential value to about +5 mV. The ionized groups of amino acid residues of insulin 
will be attracted to the positively charged LMWC via coulombic forces [37]. The zeta potential of the 
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complex is positive, which means that insulin is encapsulated in the polymer, projecting positively 
charged chains towards the external aqueous medium. Although the zeta potential value of the complex 
is positive, the surface charge of the complex will be decreased when compared to LMWC alone, which 
is expected. This facilitates absorption of the PEC to the biolipid membranes of the GIT [38]. 
 
Figure 3. Effect of 13 kDa LMWC concentration on (A) the particle size of major peaks at 
100–250 nm and (B) the zeta potential of the insulin–LMWC polyelectrolyte (I-LMWC 
PEC). The number of replicates is 6 and 3, respectively. 
The data for the effect of 13 kDa LMWC concentration and pH of the I-LMWC PEC on insulin 
association efficiency (AE) are presented in Table 4. It is well known that the formation of PEC is pH 
dependent [8,39]. The investigated pH range (6.5–7.0) in the present work is close to the pKa of chitosan 
(about 6.5) and to the isoelectric point (pI) of insulin (about 6.4). In this pH range, electrostatic, 
hydrophobic interactions as well as hydrogen bonding may be involved in PEC formation, as neutral and 
ionized chitosan species exist in an almost equal proportion [40]. 
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Table 4. Effect of 13 kDa LMWC concentration and pH on insulin association efficiency (AE). 
LMWC Concentration (mg/mL) pHf AE ± RSD (%) 
0.7 6.5 63.8 ± 2.1 
3.0 6.5 76.2 ± 3.2 
0.7 6.7 22.7 ± 2.8 
3.0 7.0 8.6 ± 4.6 
Number of replicates is 3 for each experiment. 
In the present work, the PEC using 13 kDa LMWC was prepared at different pH values of 6.5, 6.7, 
and 7.0. However, lower and high pH values were not considered (8 < pH < 5), where insulin degrades 
rapidly [8,41]. A change in pH from 6.5 to 7.0 results in a significant decrease in the value of the AE 
(from 76.5% to 8.6%) (Table 4). This may indicate that the PEC begins to precipitate at pH values higher 
than 6.5 as a result of a decrease in the solubility of the 13 kDa LMWC above its pka value (about 6.5) [8,42]. 
Such precipitation was observed for aqueous solutions of 13 kDa LMWC following pH adjustment to 
7.0. This noticeable precipitation is probably due to the formation of neutral LMWC. However, the AE 
was improved by using higher concentrations of LMWC. Such behavior was previously observed by  
Wu et al. [43]. 
2.5. In Vitro Evaluation of I-LMWC PEC and I-LMWC RM 
2.5.1. In Vitro Release 
The results for the in vitro release of insulin from the I-LMWC RM system showed a negligible 
release at pH 1.2 (<10% at 6 h), while at pH 6.8 the release is markedly increased (80% of the 
encapsulated amount at 6 h). Furthermore, the release profile at pH 6.8 was gradual and free of any 
detectable burst effects, as shown in the data in Figure 4. 
 
Figure 4. A cumulative release of insulin from insulin–LMWC reverse micelles (I-LMWC 
RMs) using 13 kDa LMWC. 
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2.5.2. In Vitro Evaluation of the Protective Effect 
The protective ability of the RMs under conditions simulating the gastric environment was evaluated 
and compared with free insulin and I-LMWC PEC. Free insulin and I-LMWC PEC were found to be 
completely degraded during incubation with pepsin, while in the RM about 90% of insulin was recovered 
after incubation with simulated gastric fluid with pepsin. These results emphasize the importance of the 
RM system in the protection of insulin from degradation by pepsin. 
2.6. Biological Activity 
The data in Figure 5 illustrate the changes in blood glucose levels of rats after oral administration of 
I-LMWC PEC after solubilization in the reverse micelles. A decrease in plasma glucose level was 
observed. The results are significantly different when compared to a blank control (p < 0.05). The reverse 
micelle preparation resulted in minimum glucose levels, about 70% after 3 h, and the reduction in 
glucose levels was maintained over a prolonged period of time. It is worth mentioning that insulin and 
I-LMWC PEC are completely degraded under conditions simulating the gastric environment, as reported 
previously [14]. However, the decrease in blood glucose levels (Figure 5) may be attributed to the 
improved stability of insulin in the reverse micelle preparation against degradation at gastric pH values 
and in the presence of enzymes in the GIT system. 
 
Figure 5. Blood glucose levels versus time profile after a single oral administration of  
50 IU/kg insulin-LMWC reverse micelle (I-LMWC RM) and a subcutaneous administration 
(SC) of 2 IU/kg insulin to STZ-diabetic rats The results are expressed as mean ± SD (n = 10 
for each group). 
3. Experimental Section 
3.1. Materials 
USP human insulin RS (26.4 USP insulin human units/mg, lot No. J0J250) was purchased from USP 
Convention (Rockville, MD, USA). Recombinant human (rh) insulin of pharmaceutical grade 
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standardized by using USP insulin human RS (potency 99.4%) was purchased from Biocon (Bangalore, 
India). Purified water and LMWCs of different molecular weights (1.3, 6, 13, 18, and 30 kDa) with 
>95% degree of deacetylation (DDA) were provided by the Jordanian Pharmaceutical Manufacturing 
Company (Naor, Jordan). LMWCs may be considered as derivative of chitosan with lower molecular 
weight, obtained by depolymerization of high molecular weight chitosan HCl (≈250 kDa and DDA 95%, 
Xiamen Xing, Shanghi, China). Oleic acid of pharmaceutical grade (purity >99%) was purchased from 
Merck (Darmstadt, Germany). Labrasol® (PEG-8 caprylic/capric glycerides) and Plurol®Oleique CG 
(polyglycerol-6-dioleate) were purchased from Gattefosse (Saint-Priest, Lyon, France). Streptozotocin 
was purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were of analytical/HPLC 
grade and purchased from Merck. 
3.2. Determination of Molecular Weight of LMWCs 
The average molecular weight of LMWCs was determined by viscosity measurements (Vibro 
viscometer, SV-10 Japan) in water. The viscosity average molecular weight was obtained using the 
Mark–Houwink’s equation, [η] = k·Ma, where [η] is the intrinsic viscosity, M is the viscosity average 
molecular weight, and the k and a values were 0.00058 and 0.69, respectively, based on a previous  
study [44]. 
3.3. Preparation of I-LMWC PEC 
LMWC (1.3, 6, 13, 18, and 30 kDa) solutions of the required concentration (0.3–7 mg/mL) were 
prepared by dissolving LMWC powder in water, adjusting the pH to 5.5 with 0.1 N NaOH, and then 
making up to the required volume with water. 
Insulin solutions (7 mg insulin/mL) were prepared by dissolving insulin powder in 1 mL of 0.1 N 
HCl, neutralized with 0.1 N NaOH and made up to a volume of 10 mL with water or 1 M Tris 
(hydroxylmethyl-aminomethane) buffer, pH 6.5. 
I-LMWC PEC was prepared by mixing equal volumes of LMWC and insulin solutions in a glass vial 
under gentle magnetic stirring and incubating for 10 min at room temperature. I-LMWC PEC 
preparations contained 3.5 mg insulin/mL and different concentrations of LMWC (0.0–3.5 mg/mL). 
3.4. Preparation of I-LMWC RM 
An RM system was prepared based on a previous study [13]. A surfactant mixture of Labrasol® and 
Plurol® Oleique CG was prepared at a 1/1 (w/w) ratio by mixing the constituents using magnetic stirring 
for 5 min. Oleic acid (80 g) and surfactant mixture (20 g) were mixed together for 5 min; 8 mL of  
I-LMWC PEC (3.5/1.5), which contained 3.5 mg insulin and 1.5 mg 13 kDa LMWC/mL, was added to 
the mixture and mixed using a magnetic stirrer (250 rpm for 5 min). 
3.5. Extraction Procedures 
For the I-LMWC PEC system, equal volumes of the sample and a solvent mixture of 0.01 N HCl and 
methanol (2/3, v/v) were mixed together. 
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For the reverse micelle system, 2 g of the sample and 4 mL of the solvent mixture were vortexed 
vigorously for 2 min, centrifuged at 4000 rpm for 15 min, and the aqueous phase collected. The samples 
were then analyzed by HPLC to determine the insulin, A-21 desamido insulin, and HMWP content  
(3 replicates); the RSD values were <5%, <0.5%, and <3%, respectively. 
3.6. HPLC Determination of Insulin 
Quantitative determination of insulin was based on the USP assay method [16]. The HPLC system 
consisted of a TSP 1000 pump system, a TSP 1000 UV-VIS detector, and a TSP AS 3000 auto-sampler 
(TSP, USA). A C18 (L1) column (particle size 5 µm), dimensions of 4.6 × 150 mm (Thermo column 
from Thermo Fisher Scientific Inc., Rockford, IL, USA), maintained at 40 °C during analysis, was used 
as the stationary phase, together with a Lichrospher 100 RP-18, 5 µm particle size guard column (Merck, 
Germany). Elution was performed isocratically (flow rate 1 mL/min) using sulfate buffer pH  
2.3-acetonitrile (73/27, v/v) as the mobile phase and UV detection at 214 nm. The injection volume was 
20 μL. The resolution, R, between insulin and A-21 desamido insulin was >2, the tailing factor for insulin 
peak was <1.8, and RSD was <1.6%. 
The resolution solution was prepared by dissolving 1.5 mg of insulin in 1 mL of 0.01 N HCl, followed 
by incubation of the solution at room temperature for not less than 3 days. Equipment control, data 
acquisition, and integration were undertaken using a ChromQuest work station. 
3.7. Size Exclusion HPLC Determination of High Molecular Weight Proteins (HMWPs) 
The method used was based on the USP limit test for HMWPs [16]. A column containing 
dihdroxypropane bound to silica packing material (L20) with a particle size of 5 μm and dimensions of 
7.8 × 300 mm was used as the stationary phase (Waters insulin HMWP column, Dublin, Ireland). Elution 
was performed isocratically (flow rate 0.5 mL/min) using a mixture of an arginine solution (1 mg/mL), 
acetonitrile, and glacial acetic acid (65/20/15, v/v) as the mobile phase and UV detection at 276 nm. The 
injection volume was 100 μL. 
Resolution solution was prepared by dissolving 4 mg of insulin containing not less than 0.4% HMWPs 
in 1 mL of 0.01 N HCl (insulin containing the indicated fraction of HMWPs was prepared by allowing 
insulin powder to stand at room temperature for about 5 days) [16]. 
3.8. HPLC Method Verification 
The two USP HPLC methods (insulin assay and limit test for HMWPs) were verified according to 
USP [45] and the International Conference of Harmonization (ICH) guidelines [46]. Standard insulin 
solutions of different concentrations (0.9, 1.75, 3.5, 7.0, and 10.0 mg/mL) were used to assess the 
linearity of the calibration plot (3 replicates). The precision of the assay was determined by analyzing 
samples of I-LMWC PEC preparations at three different insulin concentrations (1.0, 3.5, and  
10.0 mg/mL). For the assessment of the inter-day variation, samples were analyzed in triplicate (n = 3) 
on three different days. For the intra-day variation, they were analyzed 5 times (n = 5) on the same day. 
Accuracy was assessed by analyzing samples of I-CCS PEC preparations at the target concentrations of 
insulin of 3.5 mg/mL. Specificity was verified by analyzing the matrix, i.e., LMWC PEC, in the absence 
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of insulin using the extraction method stated above. Additionally, a resolution solution containing insulin 
and A-21 desamido insulin was prepared and injected. The detection limit (DL) and quantitation limit 
(QL) for the HPLC method were determined based on the standard deviation of the response and the 
slope of the calibration curve, respectively. The stability of solutions of insulin (0.9 mg/mL) was 
analyzed by HPLC at 0, 12, and 24 h of storage at room temperature. 
3.9. Stability of I-LMWC PEC 
The initial experiments were designed to incubate the I-LMWC PEC samples at 40 °C; however, as 
long periods of time (>2 months) were required to obtain indicative results, the experimental design was 
changed and the samples were incubated at a higher temperature (50 °C). Samples of I-LMWC PEC 
preparations, using LMWCs of different molecular weights and concentrations, were incubated at 50 °C 
for different periods of time. Samples were withdrawn at pre-determined intervals (0, 12, 24, 36, 48, and 
72 h) and tested for insulin, A-21 desamido insulin, and HMWP content and the physical stability of  
I-LMWC PEC preparations. In addition, the stability of insulin at different concentrations  
(0.9–10 mg/mL) in water and Tris-buffer at pH 6.5 was investigated at 50 °C. 
3.10. Immunological Bioactivity of Insulin 
Enzyme-linked immunosorbent assay (ELISA) was used to assess the immunological stability of 
insulin following formulation. Active insulin ELISA DSL-10-1600 micro-titration kits (Diagnostic 
Systems Laboratories Inc., Webster, TX, USA) were used. Insulin concentration was measured using an 
enzymatically amplified “one-step” sandwich–type immunoassay. The samples were incubated with an 
anti-insulin antibody in micro-titration wells that had been coated with another anti-insulin antibody. 
Insulin was extracted from the I-LMWC PEC (3.5/1.5 mg/mL) preparations of different molecular 
weight (1.3, 6, 13, 18, and 30 kDa), as described above, and then assayed according to the instructions 
of the manufacturer. The results were obtained by reading the optical density at 450 nm with background 
wavelength correction at 620 nm using a Bio-Rad microplate reader (Bio-Rad, Hercules, CA, USA). 
3.11. Characterization of I-LMWC PEC 
Particle size measurements were undertaken by dynamic light scattering using a Zetasizer Nano ZS 
instrument (Malvern, UK). Replicate measurements (n = 6) were carried out at 25 °C using a detection 
angle of 90°. 
Zeta potential measurements (n = 3) were also carried out using the Zetasizer Nano ZS instrument at 
25 °C using folded capillary cells integrated with gold electrodes. 
I-LMWC PECs were centrifuged at 14,000 rpm for 30 min at room temperature. The quantity of 
insulin in the supernatants was measured using HPLC and the insulin association efficiency was 
calculated accordingly [14]. The number of replicates was 3 for each experiment. 
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3.12. In Vitro Evaluation of I-LMWC PEC and I-LMWC RM 
3.12.1. In Vitro Release 
The in vitro release studies of insulin from I-LMWC RM were performed by incubating in a simulated 
gastric medium at pH 1.2 and a simulated intestinal medium, pH 6.8, (1% bile salt v/w) at 37 °C under 
continuous shaking at 50 rpm. Samples were withdrawn at specific time intervals (1, 2, 3, 4, 5, and 6 h), 
centrifuged, and analyzed for insulin release using the USP HPLC method [16]. 
3.12.2. In Vitro Evaluation of the Protective Effect 
A sample of 5 mL simulated gastric fluid (SGF) with pepsin (pH 1.2) was added to a 1 mL sample of 
free insulin solution, I-LMWC PEC solution, and a 2.0 g sample of I-LMWC PEC solubilized in the RM 
system. The samples were incubated for 1 h at 37 °C while shaking at 100 strokes/min. A 1.5 g sample 
of the RM was mixed with 5 mL of extraction solution of 0.010 M HCl and methanol (2/3, v/v), vortexed 
for 3 min, and a 100 µL sample of the aqueous layer was analyzed for insulin content by HPLC [16]. 
For insulin and I-LMWC PEC solutions, 100 µL samples were withdrawn after 1 h and analyzed for 
insulin content. 
3.13. In Vivo Pharmacological Activity 
Animal studies were conducted using adult male Sprague Dawley rats (body weight range  
250–300 g) randomized into groups (n = 10). The animals were housed in air conditioned quarters under 
a photoperiod schedule of 12 h light/12 h dark cycles. The rats received standard laboratory chow and 
tap water 3 weeks prior to the experiments. Animal care and use was performed in compliance with the 
guidelines of the Federation of European Laboratory Animal Science Association and European Union 
(Council Directive 86/609/EEC). The study protocol was approved by the Ethical Committee of the 
Jordanian Pharmaceutical Manufacturing Company (JPM), Naor, Jordan. Diabetes was induced in male 
Sprague Dawley rats by intraperitoneal injection of two doses of 80 mg/kg streptozotocin (STZ) over 
two days. STZ was freshly prepared by dissolving in 0.1 M citrate buffer, pH 4.5. Blood glucose levels 
were monitored by measuring the glucose concentrations in blood samples obtained from the tail vein 
of rats using a blood glucose meter (Gluco Dr. All Medicus, Korea, range 112–444 mg/dL). Only rats 
with a basal blood glucose level above 200 mg/dL were considered diabetic. 
STZ diabetic rats (n = 10) were randomized into different groups. Following initial blood glucose 
determinations, one group was injected with 2 IU/kg insulin and served as a positive control for insulin 
bioactivity. The other groups were given single an oral dose administration (50 IU/kg) of a blank control 
(same RM components, but without insulin), oral insulin solution, and I-LMWC RM. Blood sampling 
for glucose measurements proceeded during the experiments at specific time intervals (1, 2, 3, 4, 5, 6, 8, 
12, and 18 h) post insulin administration. 
4. Conclusions 
The insulin USP compendium method for insulin analysis and HMWPs can be used to evaluate 
insulin stability in a delivery system containing insulin as well as I-LMWC PEC. Insulin stability was 
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evaluated for insulin content, formation of HMWPs, and biological activity. In the literature, minimal 
studies are available covering these three elements, especially formation of HMWPs, which are very 
important in evaluating the suitability of the delivery system. Extraction procedures must be carefully 
carried out in order not to affect insulin results. Retention time optimization is important and currently 
insulin analysis can be executed within 20–30 min with such a convenient HPLC method. Based on 
stability studies, solutions of 3.5 mg/mL insulin and 1.5 mg/mL 13 kDa LMWC constitute the optimum 
stability formulation of the I-LMWC PEC for orally delivered insulin. Our experimental design allowed 
for the optimization of insulin formulation by determining parameters that affect the chemical and 
physical stability of insulin. The I-LMWC PEC preparation method has the advantage of not 
necessitating sonication and use of organic solvents during preparation, thereby minimizing possible 
degradation of insulin. The I-LMWC PEC system has been characterized in terms of insulin stability, 
where the study revealed that complexation with LMWC improves the stability of insulin. Both ELISA 
and in vivo studies confirmed the bioactivity of loaded insulin in the delivery system examined. 
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